Navigation Links
NxStage Extends Supply Agreement with B. Braun Medical Inc. to Include Streamline(R) Technology
Date:6/1/2009

LAWRENCE, Mass., June 1 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems in-center business has completed development of the new Streamline blood tubing sets for use on the B. Braun Dialog(R) and Dialog Plus hemodialysis systems in the U.S. In connection with this development, NxStage and B. Braun have agreed to extend their supply agreement under which NxStage will supply B. Braun with the new Streamline sets and B. Braun will provide sales, marketing, and clinical support to its U.S. customers.

"The launch of Streamline for the B. Braun machines broadens our relationship and extends the value of our product portfolio to B. Braun's Renal Therapies Division giving patients and providers greater access to NxStage's high quality, value-added in-center offerings," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "Streamline's ability to improve patient clearances and reduce cost is yet another example of NxStage's ability to innovate and bring value in the form of both clinical benefits and operational savings."

"We are pleased to broaden our relationship with NxStage by offering the unique Streamline technology to our dialysis customers," stated Samuel Amory, Vice President, B. Braun Medical Renal Therapies Division. "We look forward to leveraging Streamline's benefits with our state-of-the-art Dialog hemodialysis system and growing our business with NxStage."

NxStage's latest generation blood tubing set is the Streamline. Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes NxStage's patented LockSite(R) needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise(R)" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail B. Braun at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's Streamline blood tubing sets and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    Kristen K. Sheppard, Esq.
    VP, Investor Relations
    978-332-5923
    ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Announces Strategic Business Alliance with Asahi Kasei Kuraray Medical
2. NxStage Ranked Fourth Largest Revenue Gaining Company in Massachusetts for 2008
3. NxStage to Present at the Canaccord Adams Diabetes & Obesity Conference
4. NxStage Announces Credit Facility Amendment
5. NxStage Reports Fourth Quarter and Full Year 2008 Financial Results
6. NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year
7. iSirona Signs Reference Selling Agreement with NxStage
8. NxStage to Report Fourth Quarter and Full Year 2008 Financial Results
9. First NxStage Home Hemodialysis Patients Celebrate Five-Year Anniversary
10. NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloittes 2008 Technology Fast 500
11. NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: